| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.17 | 0.0009 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.006 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.15 | 0.009 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.01 |